GlycoVaxyn will collaborate with Janssen’s affiliate, Crucell Holland BV, on the development of the multi-valent vaccine until proof-of-concept, after which Janssen will be responsible for later ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback